Conference Coverage

Empagliflozin favorably reshaped left ventricles in HFrEF patients

Publish date: November 15, 2020

 

FROM AHA 2020

mzoler@mdedge.com

Pages

Recommended Reading

The socioeconomic revolving door of 30-day heart failure readmissions
MDedge Emergency Medicine
Empagliflozin cut PA pressures in heart failure patients
MDedge Emergency Medicine
Experts tout immediate quadruple therapy for HFrEF patients
MDedge Emergency Medicine
When should students resume sports after a COVID-19 diagnosis?
MDedge Emergency Medicine
Updated heart failure measures add newer meds
MDedge Emergency Medicine
MADIT-CRT: Resynchronization linked to fewer heart failure hospitalizations
MDedge Emergency Medicine
New return-to-play recommendations for athletes with COVID-19
MDedge Emergency Medicine
No link shown between thyroid dysfunction and heart failure
MDedge Emergency Medicine
GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit
MDedge Emergency Medicine
Intravenous iron reduces HF readmissions: AFFIRM-AHF
MDedge Emergency Medicine